What to know: Second SpaceX launch of doubleheader in Florida set for overnight hours
The liftoff is set for no earlier than 1:29 a.m. July 2 from Launch Complex 40 at Cape Canaveral Space Force Station. Backup opportunities exist until 5:28 a.m.
This mission comes just after SpaceX successfully launched the MGT-S1 weather satellite for the European Space Agency at 5:04 p.m. on July 1.
With this launch, SpaceX is going for another record-breaking booster landing, as it continues to push reusability of its fleet of first stage boosters. The Falcon 9 booster flying this mission will be seeing its 29th flight. It remains to be seen how many flights SpaceX can get out of a single Falcon 9 booster.
The mission, known as Starlink 10-25, is the latest batch of SpaceX's Starlink internet satellites. The Falcon 9 rocket will launch 27 satellites, which will join more than 7,000 Starlink satellites already in orbit. Starlink delivers internet in some of the most remote areas on Earth.
Upon liftoff, the rocket will travel on a northeast trajectory.
When is the next Florida launch? Is there a launch today? Upcoming SpaceX, Axiom, ULA rocket launch schedule at Cape Canaveral
The launch will not sound any Space Coast sonic booms, as just over eight minutes past lift off, the booster will land out on a SpaceX drone ship stationed in the Atlantic Ocean.
Check back for live updates beginning 90 minutes prior to liftoff on this page.
Countdown Timer
Brooke Edwards is a Space Reporter for Florida Today. Contact her at bedwards@floridatoday.com or on X: @brookeofstars.
This article originally appeared on Florida Today: What to know: Second SpaceX rocket launch in Florida set for overnight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Exclusive-Intel's new CEO explores big shift in chip manufacturing business
By Max A. Cherney, Jeffrey Dastin and Stephen Nellis SAN FRANCISCO (Reuters) -Intel's new chief executive is exploring a big change to its contract manufacturing business to win major customers, two people familiar with the matter told Reuters, in a potentially expensive shift from his predecessor's plans. The new strategy for Intel's foundry business would mean offering outside customers a newer generation of technology, the people said. That next-generation chipmaking process, analysts believe, will be more competitive against Taiwan Semiconductor Manufacturing Co in trying to land major customers such as Apple or Nvidia. Shares of Intel fell as much as 5% on Wednesday morning on the Nasdaq. Since taking the company's helm in March, CEO Lip-Bu Tan has moved fast to cut costs and find a new path to revive the ailing U.S. chipmaker. By June, he started voicing that a manufacturing process known as 18A, in which prior CEO Pat Gelsinger had invested heavily, was losing its appeal to new customers, said the sources, who spoke on condition of anonymity. To put aside external sales of 18A and its variant 18A-P, manufacturing processes that have cost Intel billions of dollars to develop, the company would have to take a write-off, one of the people familiar with the matter said. Industry analysts contacted by Reuters said such a charge could amount to a loss of hundreds of millions, if not billions, of dollars. Intel declined to comment on such "hypothetical scenarios or market speculation." It said the lead customer for 18A has long been Intel itself, and it aims to ramp production of its "Panther Lake" laptop chips later in 2025, which it called the most advanced processors ever designed and manufactured in the United States. Persuading outside clients to use Intel's factories remains key to its future. As its 18A fabrication process faced delays, rival TSMC's N2 technology has been on track for production. Tan's preliminary answer to this challenge: focus more resources on 14A, a next-generation chipmaking process where Intel expects to have advantages over Taiwan's TSMC, the two sources said. The move is part of a play for big customers like Apple and Nvidia, which currently pay TSMC to manufacture their chips. Tan has tasked the company with teeing up options for discussion with Intel's board when it meets as early as this month, including whether to stop marketing 18A to new clients, one of the two sources said. The board might not reach a decision on 18A until a subsequent autumn meeting in light of the matter's complexity and the enormous money at stake, the person said. Intel declined to comment on what it called rumor. In a statement, it said: "Lip-Bu and the executive team are committed to strengthening our roadmap, building trust with our customers, and improving our financial position for the future. We have identified clear areas of focus and will take actions needed to turn the business around." Last year was Intel's first unprofitable year since 1986. It posted a net loss attributable to the company of $18.8 billion for 2024. The Intel chief executive's deliberations show the enormous risks - and costs - under consideration to move the storied U.S. chipmaker back onto solid footing. Like Gelsinger, Tan inherited a company that had lost its manufacturing edge and fell behind on crucial technology waves of the past two decades: mobile computing and artificial intelligence. The company is targeting high-volume production later this year for 18A with its internal chips, which are widely expected to arrive ahead of external customer orders. Meanwhile, delivering 14A in time to win major contracts is by no means certain, and Intel could choose to stick with its existing plans for 18A, one of the sources said. Intel is tailoring 14A to key clients' needs to make it successful, the company said. AMAZON AND MICROSOFT ON 18A Tan's review of whether to focus clients on 14A involves the contract chipmaking portion of Intel, or foundry, which makes chips for external customers. Regardless of a board decision, Intel will make chips via 18A in cases where its plans are already in motion, the people familiar with the matter said. This includes using 18A for Intel's in-house chips that it already designed for that manufacturing process, the people said. Intel also will produce a relatively small volume of chips that it has guaranteed for and Microsoft via 18A, with deadlines that make it unrealistic to wait for the development of 14A. Amazon and Microsoft did not immediately comment on the matter. Intel said it will deliver on its customer commitments. Tan's overall strategy for Intel remains nascent. So far, he has updated his leadership team, bringing in new engineering talent, and he has worked to shrink what he considered bloated and slow-moving middle management. Shifting away from selling 18A to foundry customers would represent one of his biggest moves yet. The 18A manufacturing process includes a novel method of delivering energy to chips and a new type of transistor. Together, these enhancements were meant to let Intel match or exceed TSMC's capabilities, Intel executives have previously said. However, according to some industry analysts, the 18A process is roughly equivalent to TSMC's so-called N3 manufacturing technology, which went into high-volume production in late 2022. If Intel follows Tan's lead, the company would focus its foundry employees, design partners and new customers on 14A, where it hopes for a better chance to compete against TSMC. Tan has drawn on extensive contacts and customer relationships built over decades in the chip industry to arrive at his view on 18A, the two sources said. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
19 minutes ago
- Medscape
Can Metformin Prevent Severe Morning Sickness?
TOPLINE: Daily metformin use in the month before pregnancy is associated with more than 70% reduction in risk for hyperemesis gravidarum in first pregnancies. The protective effect persists in second pregnancies with 82% lower risk, even after accounting for the high recurrence risk, while cannabis use and selective serotonin reuptake inhibitors increase risk. METHODOLOGY: Researchers analyzed data from 5414 participants who reported on daily medication and substance use in the month prior to pregnancy and level of nausea and vomiting during pregnancy. Participants were recruited through the Hyperemesis Gravidarum Education and Research Foundation social media sites from January 2023 to September 2024. Analysis included logistic regression to estimate crude and multivariate associations between use of 32 common substances and severe nausea and vomiting of pregnancy/hyperemesis gravidarum. Final multivariate models incorporated tobacco use and maternal age, while number and type of additional drugs used and race/ethnicity showed minimal influence. TAKEAWAY: Prepregnancy metformin use was associated with more than 70% reduction in risk for hyperemesis gravidarum (adjusted relative risk [aRR], 0.29; 95% CI, 0.12-0.71; P = .007). Tobacco use showed significant reduction in risk (aRR, 0.51; 95% CI, 0.30-0.86; P = .011), while selective serotonin reuptake inhibitors were linked to increased risk (aRR, 2.41; 95% CI, 1.33-4.38; P = .004). Metformin use before a second pregnancy was associated with 82% lower risk for severe nausea and vomiting/hyperemesis gravidarum (adjusted odds ratio [aOR], 0.18; 95% CI, 0.06-0.59; P = .005), even after adjusting for an 86% recurrence risk. Cannabis use (aOR, 3.48; 95% CI, 1.80-6.75; P < .001) and selective serotonin reuptake inhibitors (aOR, 1.84; 95% CI, 1.12-3.04; P = .016) before a second pregnancy were associated with increased risk. IN PRACTICE: 'Metformin, which is routinely used pre- and post-conception, may be a safe and affordable treatment to offer patients with a prior history of hyperemesis gravidarum to decrease the chance of recurrence. Clinical trials are warranted to investigate metformin use prior to pregnancy to lower hyperemesis gravidarum risk, thereby mitigating the associated adverse maternal and offspring outcomes,' wrote the authors of the study. SOURCE: The study was led by Neelu Sharma, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California in Los Angeles. It was published online in American Journal of Obstetrics and Gynecology. LIMITATIONS: The hyperemesis gravidarum-enriched approach to participant recruitment may have introduced selection bias, as individuals with multiple occurrences may have been more likely to participate. However, the authors noted that similar recurrence rates were reported in previous prospective studies. Additionally, the indication, timing, and dosage for each medication or substance was unknown. While conditions commonly treated with metformin like diabetes and polycystic ovary syndrome have been associated with increased risk for hyperemesis gravidarum, any confounding by indication would bias results upward rather than explain the observed inverse associations. DISCLOSURES: Marlena S. Fejzo disclosed being a consultant for NGM Biosciences, receiving stock and fee for service. The remaining coauthors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
20 minutes ago
- Yahoo
Trending tickers: Oracle, TSMC, Rigetti Computing, Currys and Watches of Switzerland
Shares in Oracle (ORCL) notched a fresh high on Wednesday, after it was reported that OpenAI had signed a data centre deal with the technology company. In an Securities and Exchange Commission filing on Monday, Oracle said that CEO Safra Catz was expected to tell colleagues that the company's current fiscal year was off to a "strong start", with its MultiCloud database revenue continuing to grow at more than 100%. In addition, Catz was expected to say that Oracle had signed multiple large cloud services agreements, including one that is expected to contribute more than $30bn (£21.9bn) in annual revenue starting in the 2028 financial year, but did not name the customer. Read more: FTSE 100 LIVE: Stocks rise while pound and UK bonds recover as Starmer backs Reeves Bloomberg reported on Wednesday that OpenAI had agreed to computing power from Oracle data centres as part of the Stargate initiative, citing people familiar with the work. This would reportedly total 4.5 gigawatts of data centre power in the US. According to one of the sources, the Stargate agreement makes up at least part of the $30bn contract disclosed in the SEC filing on Monday. A spokesperson for Oracle had not responded to Yahoo Finance UK's request for comment at the time of writing. US-listed shares in TSMC (TSM) rose around 4% on Wednesday after Needham raised its price target on the chipmaker from $225 to $270 per share. TSMC, which is the world's largest contract chipmaker, also got a boost from reports that Intel's recently appointed CEO was considering a major shift in its chip manufacturing process. Read more: Pound recovers as Starmer eases market panic over chancellor Reuters reported that Intel (INTC) CEO Lip-Bu Tan was considering scrapping the American chipmaker's efforts for the 18A manufacturing process, which included enhancements that were meant to enable the company to compete with TSMC's capabilities. Instead, Intel is reportedly exploring a change to the contract manufacturing business, which would mean offering outside customers a newer generation of technology. Reuters reported that analysts believe this process would be more competitive against TSMC in aiming to land key customers, such as Apple (AAPL) or Nvidia (NVDA). Another tech stock in focus on Thursday was Rigetti Computing (RGTI), after it surged 15% in the previous session. The jump came after Cantor Fitzgerald analyst Troy Jensen initiated a "overweight" rating on the Rigetti, along with two other quantum computing companies, according to a Barron's report. Jensen reportedly said that the competitive ecosystem of quantum computing "positions Rigetti to benefit from the efforts of others". He also initiated "overweight" ratings on D-Wave (QBTS) and IonQ (IONQ). On the London market, shares in Currys (CURY.L) jumped 7.5% on Thursday morning, as the electronics retailer reported stronger sales and profits for the past year. Currys posted group adjusted profit before tax of £162m ($221m), which was up 37% year-on-year, while group revenue of £8.7bn was up 3%. In addition, the company said trading in the early part of the new financial year has been in line woth expectations. Stocks: Create your watchlist and portfolio Dan Lane, lead analyst at Robinhood UK, said: "What a year for Currys. Profits before tax are in rude health and net cash of £184m gives the balance sheet a solid basis to make even bigger strides this year. "UK consumer confidence is growing and if it has bottomed, Currys could benefit even more from Britons feeling happier to spend on bigger electrical purchases. Inflation is subsiding and while wage growth is slowing, consumers are clearly considering the worst hits to their pockets to be behind them." FTSE 250-listed (^FTMC) company Watches of Switzerland (WOSG.L) fell 6.4% on Thursday morning, after the retailer reported a fall in annual pre-tax profits. Watches of Switzerland reported record revenue of £1.65bn for year ended 27 April, which was up 8% year-on-year. However, statutory profit before tax was down 18% to £76m. Barclays analysts, which have an "overweight" rating on the stock, said in a note on Thursday that there were "no fireworks" in the results but the fact that the company's guidance is close to consensus is "reassuring". Read more: Stocks that are trending today They said: "Whilst we have lowered our forecasts slightly, this is largely FX driven, and the mid-point of the company's guidance (at constant currency) is close to company consensus. We do not believe that these results move the investment debate on substantially. We now forecast PBT (profit before tax) in FY26 of £137m, a fraction higher than £136m reported in FY25." "This is clearly a long way off the growth delivered during the company's stronger years, but given the potential headwinds from tariffs, we believe that if broadly flat profits can be delivered, it would remove some of the more significant downside scenarios and investor concerns," Barclays' analysts added. Read more: 'Too soon' to see price effects from tariffs, says Bank of England's Bailey Global economy to slow amid 'most severe trade war since 1930s', says Fitch UK economy grew 0.7% in first quarter of the yearInicia sesión para acceder a tu cartera de valores
